MARKET

DNTH

DNTH

Dianthus Therapeutics Inc
NASDAQ
90.00
+3.97
+4.61%
Closed 19:31 11/09 EST
OPEN
88.21
PREV CLOSE
86.03
HIGH
91.82
LOW
84.41
VOLUME
704.03K
TURNOVER
0
52 WEEK HIGH
117.88
52 WEEK LOW
34.29
MARKET CAP
5.07B
P/E (TTM)
-22.5553
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DNTH last week (1102-1106)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Adicet Bio (ACET), Dianthus Therapeutics (DNTH)
TipRanks · 3d ago
Dianthus Therapeutics (DNTH) Gets a Buy from Guggenheim
TipRanks · 3d ago
Dianthus Therapeutics (DNTH) Could Be 41% Undervalued After Its Earnings Beat
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Bruker (BRKR) and Envista Holdings (NVST)
TipRanks · 4d ago
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Geron (GERN)
TipRanks · 4d ago
Dianthus Therapeutics (DNTH) Gets a Buy from Stifel Nicolaus
TipRanks · 4d ago
Earnings Beat Could Be A Big Moment For Dianthus Therapeutics Stock (DNTH)
Simply Wall St · 5d ago
More
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.

Webull offers Dianthus Therapeutics Inc stock information, including NASDAQ: DNTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNTH stock methods without spending real money on the virtual paper trading platform.